BUSINESS ACQUISITIONS

6 Months Ended

Jun. 30, 2019

Business Combination Disclosure [Text Block]

BUSINESS ACQUISITIONS AND DISPOSITIONS

On June 3, 2019, the Company's CDD segment completed the acquisition of Envigo's nonclinical contract research services business, expanding CDD's global nonclinical drug development capabilities with additional locations and resources. Envigo also completed the acquisition of the Covance Research Products (CRP) business, which was part of the CDD segment. The two companies will continue to collaborate through a multi-year, renewable supply agreement. The Company paid cash consideration of $601.0, received a floating rate secured note of $110.0, and recorded a loss on sale of CRP of $8.8. The Company funded the transaction through a new term loan facility.

The preliminary valuation of acquired assets and assumed liabilities as of June 3, 2019, include the following:



Consideration Transferred
Cash consideration	$	601.0
Fair value of CRP	110.0
Total	$	711.0

	Preliminary
Net Assets Acquired
Cash and cash equivalents	$	15.1
Accounts receivable	16.5
Unbilled services	26.5
Inventories	4.5
Prepaid expenses and other	3.5
Property, plant and equipment (including ROU operating lease assets)	99.1
Deferred tax asset	25.5
Goodwill	432.2
Customer relationships	125.8
Trade name and trademarks	0.6
Other assets	9.9
Total assets acquired	759.2
Accounts payable	15.4
Accrued expenses and other	11.6
Unearned revenue	49.9
Operating lease liabilities	15.0
Other liabilities	66.3
Total liabilities acquired	158.2
Net Envigo assets acquired	601.0
Floating rate secured note receivable due 2022	110.0
Total	$	711.0

The amortization periods for intangible assets acquired are 11 years for customer relationships.

The Envigo transaction contributed $16.5 and $0.7 of revenues and operating income, respectively, during the three and six months ended June 30, 2019.

The purchase price allocation for the Envigo transaction is still preliminary and subject to change. The areas of the purchase price allocation that are not yet finalized relate primarily to intangible assets, goodwill, fixed assets and the impact of finalizing deferred taxes. Accordingly, adjustments may be made as additional information is obtained about the facts and circumstances that existed as of the valuation date. The Company expects these purchase price allocations to be finalized by the second quarter of 2020. Any adjustments will be recorded in the period in which they are identified.

During the six months ended June 30, 2019, the Company also acquired various businesses and related assets for approximately $117.7 in cash (net of cash acquired). The purchase consideration for all acquisitions year to date has been allocated to the estimated fair market value of the net assets acquired, including approximately $90.7 in identifiable intangible assets and a residual amount of non-tax deductible goodwill of approximately $53.8. The amortization periods for intangible assets acquired from these businesses range from 11 to 15 years for customer relationships. These acquisitions were made primarily to extend the Company's geographic reach in important market areas, enhance the Company's scientific differentiation and to expand the breadth and scope of the Company's CRO services. The excess of the fair value of the consideration conveyed over the fair value of the net assets acquired was recorded as goodwill. The goodwill reflects the Company's expectations to utilize the acquired businesses’ workforce and established relationships and the benefits of being able to leverage operational efficiencies with favorable growth opportunities in these markets.

Additionally, the Company divested its food solutions and forensic testing services business in the United Kingdom (U.K) and the U.S. in 2018. Total operating income for the three divested businesses was $3.4 and $5.4 for the three and six months ended June 30, 2018, respectively.